In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Aimmune Therapeutics (AIMT), with a price target of $24. The company’s shares closed yesterday at $19.97, close to its 52-week low of $19.25.
Archila observed:
“We are reiterating our Hold rating on AIMT shares after the company reported its 1Q19 financial and business update. In the near-term, we see limited stock-moving catalysts for AIMT given: (1) the FDA adcom probably doesn’t take place until late 2019; (2) AR101 approval and launch are not expected until early 2020 and; (3) the lack of clinical catalysts from other programs in AIMT’s food allergy pipeline. Despite the recent pullback in shares and the general sense that AR101 will be approved, we continue to remain cautious on the peanut immunotherapy category as a whole and think AIMT shares will trade in range ahead of AR101’s key regulatory catalysts.”
According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.2% and a 33.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Principia Biopharma Inc.
Currently, the analyst consensus on Aimmune Therapeutics is a Strong Buy with an average price target of $53.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.12 and a one-year low of $19.25. Currently, Aimmune Therapeutics has an average volume of 596.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
